Opinion

Video

Clinical Insights into the COMMANDS Trial

The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Video Player is loading.
Current Time 0:00
Duration 6:47
Loaded: 0%
Stream Type LIVE
Remaining Time 6:47
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Newsletter

Stay up to date on the most recent and practice-changing oncology data